The protein tyrosine phosphatase receptor type G (PTPRG), also known as PTPγ, is a member of the receptor-type protein tyrosine phosphatase (PTP) family, which regulates cellular signaling by dephosphorylating tyrosine residues on target proteins. It plays a critical role in cell adhesion, migration, and proliferation, and is implicated as a tumor suppressor in various cancers. Structurally, PTPRG contains an extracellular domain with fibronectin type III repeats for ligand binding, a transmembrane region, and an intracellular catalytic phosphatase domain. Alternative splicing generates multiple isoforms with distinct functional roles.
PTPRG antibodies are essential tools for studying its expression, localization, and interactions in both normal and pathological contexts. In research, these antibodies are used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence to investigate PTPRG's downregulation in cancers (e.g., lung, glioblastoma) and its association with poor prognosis. Dysregulated PTPRG expression is also linked to neurological disorders, including schizophrenia and autism, due to its role in neural development and synaptic plasticity.
Studies suggest PTPRG interacts with cell adhesion molecules and growth factor receptors, modulating pathways like β-catenin and RTK signaling. Antibodies targeting specific domains help elucidate its tumor-suppressive mechanisms and potential as a therapeutic target or biomarker. Ongoing research aims to clarify its ligand interactions and signaling networks in disease progression.